It is increasingly discussed in longevity and preventive-medicine circles as a way to achieve: Metabolic balance without extreme appetite suppression Sustained tolerability by avoiding gastrointestinal side effects Lower cost and simplified maintenance regimens Long-term receptor engagement for cardiometabolic and neuroprotective benefits While this approach remains off-label and under formal investigation, the biological rationale is strong: GLP-1 signaling is not binary but dose-responsive, and even partial activation may influence inflammatory, vascular, and cognitive pathways linked to aging
To date, major clinical trials have only tested GLP1 agonists in the form theyre FDA-approved for primarily as once-weekly injections
Emerging evidence even suggests these medications may positively influence energy expenditure and overall metabolic health, although research in this area is still ongoing
Drucker has found that the cells in the gut that produce GLP-1 seem to detect pathogens, releasing the hormone as part of the bodys response to injury or infection
However, this inhibitory effect is significantly weakened in patients with T2DM, indicating that its potential application in diabetes treatment requires further investigation
It took me a long time to understand that that wasnt me, especially in my sport
